Sunshine Lake Pharma Co (6887) investor relations material

Executive summary

• Revenue for H1 2026 was RMB 1,075.31 million, down 44.5% year-over-year due to a significant decline in sales of the core influenza drug Kewei as the epidemic eased.

• Gross profit dropped 60.6% to RMB 578.17 million, with gross margin falling to 53.77% from 75.74% year-over-year.

• Net loss attributable to equity shareholders was RMB 596.42 million, a significant increase from the prior year's loss.

• The company maintained a robust R&D pipeline, advanced innovative drugs, AI-driven development, and international expansion, including FDA approval and US launch of Insulin Glargine.

• No interim dividend was declared for the period.

Financial highlights

• Revenue: RMB 1,075.31 million (down 44.5% YoY).

• Gross profit: RMB 578.17 million (down 60.6% YoY); gross margin: 53.77%.

• Net loss: RMB 596.42 million; basic and diluted loss per share: RMB 1.09.

• Gearing ratio increased to 135% (from 105% at end-2025); quick ratio decreased to 0.61.

• Bank loans and other borrowings increased to RMB 5,222.91 million.

Outlook and guidance

• The company aims to enhance R&D efficiency, expand its innovative drug pipeline, and accelerate internationalization, focusing on AI-driven R&D.

• Plans to invest strong operating cash flow into R&D, streamline decision-making, and optimize production and distribution systems.

• Focus on sustainable growth, brand building, and digital transformation.